{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreias6pnrw47gef7wd2snntxzergsepou6iakfhymxvve2d7avccj7a",
    "uri": "at://did:plc:yhmwewfk3g3hhkrw2gf4ypna/app.bsky.feed.post/3mlzlp4wduzj2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiewnpd6inmyx63l5ama6vrhaseggscmdohrgc4figoi7ppxc62myy"
    },
    "mimeType": "image/jpeg",
    "size": 40918
  },
  "path": "/2026/05/16/geranylgeraniol-for-bronj-prevention/",
  "publishedAt": "2026-05-17T03:33:26.000Z",
  "site": "https://dissentwatch.com",
  "tags": [
    "#Column1"
  ],
  "textContent": "STORY AT-A-GLANCE Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious complication affecting patients taking osteoporosis and cancer medications like Fosamax, Boniva, and Zometa, and once the jaw bone dies, there is currently no effective treatment Bisphosphonates work by the same mechanism as statins — they inhibit the mevalonate pathway — which means they cause […]",
  "title": "Geranylgeraniol for Bisphosphonate-Related Osteonecrosis of the Jaw — A Second Critical Application"
}